RxDoctor Payments Data

Debra Murdick

Family · Indiana, PANPI 1043860430

Payments from drug & device makers

$714in general payments, 2019–2025

Across 36 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$105
  • Indivior Inc.$94
  • Lilly USA, LLC$71
  • AstraZeneca$65
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$47
  • Bristol Myers Squibb$37
  • plus $296 from 12 others

What the payments were for

  • Food & beverage$714100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$714 in reported general payments places this provider in the 65th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$26,864
Medicare patients
183
Services billed
537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide16$39,957
XareltoRivaroxaban39$29,681
EliquisApixaban28$29,226
JardianceEmpagliflozin26$28,468
OzempicSemaglutide19$18,691
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$13,535
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl92$12,143
Buprenorphine17$6,067
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$2,760
Levothyroxine Sodium97$1,665
Atorvastatin Calcium99$1,585
Buprenorphine Hcl31$1,501
Nano 2nd Gen Pen NeedlePen Needle, Diabetic11$1,469
Albuterol Sulfate HfaAlbuterol Sulfate39$1,318
Oxycodone Hcl59$1,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$34$13,53514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,717 family providers in Pennsylvania.

Other family in Indiana

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →